Tag Archives: United States Patent and Trademark Office

MIT: Stanford v. Roche “Could Have Adverse Impact on Tech Transfer”

Link to MIT News article (“MIT to file amicus brief in intellectual-property case“): The brief argues that the case threatens to undermine the Bayh-Dole Act, a federal law that has played a central role in America’s system of innovation. Enacted in 1980 as an amendment to the Patent Act, Bayh-Dole expanded and accelerated the transformation of ideas in the lab into the products, jobs and revenues of commercial enterprise.

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: ,

A Disin‘gene’uous Lawsuit: ACLU Challenges DNA Patents

From the mass production of life-saving medicines in cell cultures to the screening of our blood supply for life-threatening viruses, patented DNA molecules (often referred to as “gene patents”) are used in many ways to benefit society.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

Burrill Report Podcast: Implications of Gene Patent Ruling

The Burrill Report podcast on the impact of the recent decision invalidating patents on genetic materials.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Tomorrow: BIO is “To the Point” on Gene Patenting

BIO is participating in an NPR segment at approximately 2:08pm ET tomorrow on the nationally-syndicated national radio program “To the Point” which originates in NYC. It should air on WAMU in DC, too, for those of you in the Nation’s capital.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

IP Professors: 12-Year Data Exclusivity a Win-Win for Patient Access & Biotech Innovation

David E. Adelman of the University of Texas School of Law and Christopher M. Holman of the University of Missouri – Kansas City School of Law recently published analysis on the “sideshow” of the data exclusivity debate in Washington.

Adelman and Holman use a cost-benefit analysis that incorporates the most important legal precedents and case law today in concluding that “policymakers should focus on mitigating the systematic barriers to entry that pose much greater and longer-term obstacles to lower-cost biotech drugs.” Specifically, the draft paper provides solid analysis of the need for 12-year data exclusivity, which the authors describe as a perfect balance between providing access to important medicines to patients, and creating the incentives needed for investors and companies to prepare (and survive) the regulatory approval process for follow-on biologics.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,